We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CHRO market cap is 15.55M. The company's latest EPS is USD -1.2245 and P/E is -2.16.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|
| USD (US$) | USD (US$) | ||
| Total Revenue | 0 | 0 | 0 |
| Operating Income | -1.93M | -1.76M | -2.05M |
| Net Income | -2.56M | -1.77M | -1.7M |
| Year End 31 December 2023 | 2022 | 2023 |
|---|---|---|
| USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 |
| Operating Income | -2.32M | -6.86M |
| Net Income | -2.46M | -7.38M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|
| USD (US$) | USD (US$) | ||
| Total Assets | 4.03M | 2.6M | 2.14M |
| Total Liabilities | 2.9M | 2.79M | 3.57M |
| Total Equity | 1.13M | -183k | -1.43M |
| Year End 31 December 2023 | 2022 | 2023 |
|---|---|---|
| USD (US$) | USD (US$) | |
| Total Assets | 55k | 96k |
| Total Liabilities | 3.76M | 6.54M |
| Total Equity | -3.71M | -6.45M |
| Market Cap | 15.55M |
| Price to Earnings Ratio | -2.16 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 166.04 |
| Price to Book Ratio | -2.47 |
| Dividend Yield | - |
| Shares Outstanding | 6.03M |
| Average Volume (1 week) | 3.71M |
| Average Volume (1 Month) | 997.22k |
| 52 Week Change | -57.00% |
| 52 Week High | 6.00 |
| 52 Week Low | 0.45 |
| Spread (Intraday) | 0.08 (3.01%) |
| Company Name | Channel Therapeutics Corporation |
| Address |
50 west liberty street reno, nevada 89501 |
| Website | https://channeltherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
